Renovo Group has reported positive trial results for Juvista Paediatric, a new formulation of Juvista for children indicated to improve the appearance of scars.

The trial met its primary endpoint, where single dose of Juvista Paediatric statistically significantly improved the appearance of scars compared to a placebo.

The trial also confirmed the optimal dose of Juvista for an ongoing adult Phase III efficacy study, which was determined as 500ng/100µl/linear cm of wound margin administered twice.

The double-blind and placebo-controlled study enrolled 84 healthy adults, who either received single doses of Juvista Paediatric or a placebo immediately after the wound closure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData